Amarin Corp Plc (AMRN)

[north40000]

Good. In light of the first sentence of your post, others here may not know or have recognized that counsel for Merck in the Keytruda patent litigation with JHU is the same counsel that Amarin is using in the Amarin v. Hikma matter now on appeal to the CAFC. I wonder, like you, why Amarin has not asked for reexamination of its 4 patents in the PTO before the Board of Patent Appeals and Interferences. The procedural effect of FRCP Rule 60(d)(3) “at any time” seems equally applicable in both the Federal Courts(Hazel-Atlas case) and BPAI. But the timing and enhanced litigation cost may not be appropriate in light of other matters Amarin is considering. See letter to shareholders and CEO Holts remarks at JPM.